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Background/aim: A successful planning methodology for patients with hemoptysis promises overall improvement in patient care.
Conducted in a reference center for chest diseases, the present study aims to analyze characteristics and predictors of interventional
methods in patients with recurrent hemoptysis.
Materials and methods: The present study is a single-center, retrospective observational study. Between 2015 and 2018, 5973 patients with
follow-up data until 2021 requiring more than one hospitalization due to recurrent hemoptysis were investigated. Patient characteristics,
the amount of hemoptysis, baseline admission parameters, interventional procedures of bronchial artery embolization (BAE), fiberoptic
bronchoscopy, rigid bronchoscopy, and surgical resections applied were analyzed according to number of hospitalizations and outcome.
Results: Hospital admission numbers were higher in patients with sequela of tuberculosis, bronchiectasis and lung cancer. While lung
cancer was the most frequent underlying reason in recurrent admissions, it was determined that as the amount of bleeding increased,
the number of admissions also increased to the hospital, and BAE and rigid bronchoscopy were performed more frequently in the
groups with less frequent admissions. There was no statistically significance between the amount of bleeding, and the interventional
procedure alone or in combination with another procedure (p > 0.05).
Conclusion: In conclusion, patients with certain diseases may experience frequent hospital admissions due to hemoptysis. Recurrent
admissions may get better results with BAE and rigid bronchoscopy. We think that these procedures should be preferred in the
foreground of suitable patient selection in line with available facilities and experience.
Key words: Hemoptysis, bronchoscopy, embolization, surgery, rigid

1. Introduction
Hemoptysis is defined as mixed-blood or exclusively blood
expectoration from lower respiratory tracts [1,2]. It is
encountered frequently in medical practice as it overlaps
with many underlying diseases. Hemoptysis may be lifethreatening for about 5%–15% of the cases [3,4]. Massive
hemoptysis is defined as 100–1000 mL or 300–600 mL
bleeding amount accumulated within 24 h and requires
immediate management [5,7]. Since the management of
hemoptysis requires simultaneous use of different methods
in both diagnosis and treatment, multidisciplinary
collaboration is vital. After the hemodynamic stabilization
is established, conservative interventional methods of

urgent surgical procedure, bronchial artery embolization
(BAE), and rigid bronchoscopy should be considered [8,9].
Although the surgery option is perceived as
parenchyma-protective and thus favored in the early
phases, urgent surgical interventions in hemoptysis
corresponds to a 40% higher rate of mortality compared
to the elective procedures [10]. Either BAE is not suitable
or in patients with recurrent hemoptysis, a 48-h waiting
period is recommended with lower mortality compared
to opting for an early surgery. BAE has a success rate of
80%–99% despite a 12%–17% recurrence rate [9,11,12].
Fiberoptic bronchoscopy visualizing bronchi can
be utilized to localize the site of bleeding in massive
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hemoptysis in 73%–93% of the cases, whereas localization
success declines in mild bleeding [13-16]. Timing and
speed of the intervention is critical in this phase. Rigid
bronchoscopy, on the other hand, with a clear vision
and respiratory safety, provides bleeding control and
respiratory hygiene. To reach lower respiratory tract,
fiberoptic bronchoscopy in conjunction with the rigid
bronchoscopy allows complete and clear visualization
[17]. Effective management of hemoptysis in experienced
centers may decrease recurrence rates.
Performed in a reference center with high bed
capacity, the aim of this study is to evaluate the success
rates of alternative interventional methods in patients with
recurrent hemoptysis.
2. Patients and methods
The present study is a single-center and retrospective,
observational study. The data of the patients who visited
emergency department (ED) with hemoptysis between
January 2015 and January 2018, with a follow-up data until
2021, were retrieved from the hospital database system.
Among 22,212 patients with at least one ED visit
with hemoptysis, 5973 patients with at least one
hospitalization were included in the study (Figure). The
study was conducted in accordance with the principles
of the Declaration of Helsinki and the study protocol was
approved by the Ethics Committee of Health Sciences
University İstanbul Yedikule Chest Diseases Training and
Research Hospital (No: 2020-40)

2.1. Organization of the ED
In ED, after hemodynamic stabilization, adrenalin
nebulization is used; in localized cases, cold compress
and intravenous tranexamic acid are administered. When
needed, fresh plasma and thrombocyte infusion are used
in patients with coagulation disorder. When needed,
interventional procedures such as rigid bronchoscopy and
bronchial artery embolization are performed within the
first 48 h in patients with hemoptysis. For BAE, cases are
referred to a single-center radio-diagnostic unit (Ö.K.).
Transfemoral way is used to access the routine bronchial
circulation. Polyvinyl alcohol of 300–500 nm is used in
embolization.
2.2. Recorded parameters
Patients’ demographics, comorbid diseases, date of
hospital admission, duration of hospitalization, invasive
procedures throughout the hospitalization were noted. The
invasive procedures were flexible or rigid bronchoscopy,
BAE, and surgical procedures which were decided by
the expert team. The following values at admission were
recorded as baseline parameters: complete blood count
(CBC), platelet count (Plt), liver function tests (aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT)), and renal function tests. Bleeding amounts of all
patients at ED visit were classified as minor, moderate, or
massive.
During follow-up, all interventional methods of
either flexible or rigid bronchoscopy, BAE, and surgical
procedures applied for hemoptysis were investigated.

Figure. Flowchart of patient inclusion.
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All cases’ survival statuses were checked via National
Death Registration. Censored via death status, patients’
readmissions with recurrent hemoptysis were recorded
until January 2021. Baseline parameters and invasive
procedures according to recurrence of hemoptysis were
analyzed.
2.3. Definitions
In present study, the accepted classification for massive
hemoptysis is the bleeding amount of 100–1000 mL or
300–600 mL within 24 h [5-7]. Severe hemoptysis is
defined as a bleeding amount of 150 mL within 12 h [8].
Moderate hemoptysis: bleeding amount of 100–300 mL/
day and mild hemoptysis is described as bleeding less than
100 mL/day [10].
2.4. Study design
Recorded parameters at hospital admission with
hemoptysis and invasive procedures undertaken
were investigated. The relationship between recorded
parameters and patients’ readmissions were analyzed.
Additionally, the relationship between the procedures
undertaken and mortality was investigated.
2.5 Statistical analysis
SPSS 21.0 (IBM, Armonk, NY, USA) program was used
for statistical analysis. Descriptive statistics are presented
as mean, standard deviation, frequency, and percentages.
Recurrence rates are shown as categorical variables;
comparisons were made via chi-squared test. Likewise, the
chi-squared test was used to compare the bleeding amount
and the interventional procedures. Bonferroni correction
was made for pairwise comparisons of the variables that
were significant as a result of the chi-squared test. The
compliance of the follow-up duration with the normal
distribution was evaluated in line with the Shapiro–Wilk
test. The Mann–Whitney U test was used to compare the
procedures performed in the two groups, since it did not
meet the normal distribution assumption. The Kruskal–
Wallis H test was used to compare laboratory parameters
with the number of admission. Dunn’s test was used
in post hoc analysis. The p < 0.05 value was accepted as
significant.
3. Results
Of all the 5973 patients, the mean age was 50 ± 16 (14–
91) and 4249 (71%) were male. Current smoking rate
was 37% while 55% were never-smoker. During followup, hemoptysis recurred twice in 2644, thrice in 1543,
and four times or more in 1786 patients. Age (49 ± 16;
50 ± 16; 49 ± 16; p = 0.959), sex, and smoking status did
not affect the frequency of recurrence (p = 0.296, p =
0.913, respectively). Among recurrent cases, lung cancer
(n = 373), bronchiectasis (n = 248), tuberculosis (TB)
sequelae (n = 166), active TB (n = 125), and pulmonary
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thromboembolism (n = 59) coexisted. Comorbid
diseases such as active tuberculosis (TB), history of TB,
bronchiectasis, and lung cancer amplified recurrence (p <
0.001, for all) (Table 1).
The interventions for patients with lung cancer were
BAE in 40%, (n = 150), rigid bronchoscopy in 24% (n =
90), rigid bronchoscopy + BAE in 11% (n = 42), and BAE
+ rigid bronchoscopy + surgical resection in 2% (n = 8). In
bronchiectasis, 40% (n = 100) underwent BAE, 30% (n =
74) rigid bronchoscopy, 14% (n = 35) rigid bronchoscopy
+ BAE, and 3% (n = 8) underwent rigid bronchoscopy +
BAE + surgical resection.
As for laboratory parameters, baseline lower
hemoglobin and hematocrit values were correlated with
higher number of admissions which may also be related to
blood loss due to hemoptysis (p < 0.001, for all). The other
total blood count and biochemistry values had no impact
on recurrence (Table 2).
A statistically significant correlation was found between
the admission numbers and BAE, number of BAEs, and
rigid bronchoscopy in the study (p < 0.001, p = 0.048 and
p < 0.001, respectively). Table 3 shows the relationship
between admission numbers and interventional methods.
A statistically significant correlation was found
between the amount of bleeding and the operation, type
of operation, BAE, and number of BAEs in the study (p
= 0.046, p = 0.040, p = 0.003, and p = 0.034, respectively)
(Table 4). No statistical significance was observed in terms
of performing a distinct interventional procedure or a
combination of interventional procedures with recurrence
rates and bleeding amount (p > 0.05) (Table 5,6).
Overall follow-up duration was 1260 ± 905 days in all
patients whereas lung cancer patients were followed up for
660 ± 354 days. Patients undergoing BAE were followed
up longer compared to patients undergoing BAE + rigid
bronchoscopy and BAE + surgical resection (p = 0.011
and p < 0.001, respectively). Sole rigid bronchoscopy
group had a longer follow-up period compared to the rigid
bronchoscopy + operation group (p = 0.022). There was no
statistical difference in the follow-up period of the group
undergoing rigid bronchoscopy and rigid bronchoscopy +
BAE (p > 0.05) (Table 7).
4. Discussion
We believe that our study contributes to the existing
literature by showing that the combination of BAE and
rigid bronchoscopy has the potential to moderate hospital
admission episodes of the patients compared to the separate
use of each modality. We found that as bleeding increases,
bundling of different interventional methods becomes
more common. BAE and rigid bronchoscopy were the
most frequently combined methods applied to our patients
who also happened to have the longest follow-up terms.
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Table 1. Comparison of number of admissions and clinical parameters.
Total

Twice

Thrice

≥ four times

Female

1724 (28.86 )

790 (29.88)

430 (27.87)

504 (28.22)

Male

4249 (71.14 )

1854 (70.12)

1113 (72.13)

1282 (71.78)

Current smoker

2189 (36.85 )

985 (37.44)

559 (36.35)

645 (36.4)

Never-smoker

3249 (54.69 )

1428 (54.28)

850 (55.27)

971 (54.8)

Former smoker

503 (8.47 )

218 (8.29)

129 (8.39)

156 (8.8)

No

5848 (97.91 )

2582 (97.66)

1519 (98.44)

1747 (97.82)

Yes

125 (2.09 )

62 (2.34)

24 (1.56)

39 (2.18)

No

5807 (97.22 )

2599 (98.3)

1504 (97.47)

1704 (95.41)

Yes

166 (2.78 )

45 (1.7)

39 (2.53)

82 (4.59)

No

5725 (95.85 )

2557 (96.71)

1481 (95.98)

1687 (94.46)

Yes

248 (4.15 )

87 (3.29)

62 (4.02)

99 (5.54)

No

5600 (93.76 )

2498 (94.48)

1464 (94.88)

1638 (91.71)

Yes

373 (6.24 )

146 (5.52)

79 (5.12)

148 (8.29)

p

Sex
0.296

Smoking status
0.913

TB
0.216

TB sequela
<0.001

Bronchiectasis
<0.001

Lung cancer
<0.001

Pulmonary embolism/DVT
No

5914 (99.01 )

2622 (99.17)

1535 (99.48)

1757 (98.38)

Yes

59 (0.99 )

22 (0.83)

8 (0.52)

29 (1.62)

0.003

DVT: deep vein thrombosis, TB: tuberculosis. In paired comparisons; patients suffering from TB sequela experienced more frequent
admissions than both twice and thrice. For bronchiectasis, four times admissions were more frequent than twice. Four times admissions
were significantly higher than twice and thrice in lung cancer and in pulmonary emboli or deep vein thrombosis patients.
Table 2. Comparison of number of admissions and laboratory parameters.
Total

Twice

Thrice

≥ four times

p

Hemoglobin (g/dL)

13.4 ± 2

13.5±2

13.6±1.9

13.3±2

0.001

Hematocrit (%)

40.1 ± 5.5

40.1±5.5

40.4±5.1

39.6±5.8

0.001

Platelets

258.1 ± 90.2

257.7 ± 87.6

255.54 ± 90.45

260.9 ± 93.6

0.322

Creatinine (mg/dL)

0.91 ± 0.76

0.88 ± 0.66

0.92 ± 0.81

0.93 ± 0.84

0.219

BUN (U/L)

34.5 ± 16.1

34.6 ± 16.6

34.6 ± 16.9

34.1 ± 14.4

0.729

ALT (U/L)

21.8 ± 22

22.4 ± 23.7

21.6 ± 18.4

21.1 ± 22.1

0.359

AST (U/L)

24.3 ± 17.4

24.7 ± 19.7

24.7 ± 17.8

23.3 ± 13.1

0.095

GGT (U/L)

40.1 ± 57.4

40.7 ± 53.9

37.6 ± 53.1

41.1 ± 64.

0.587

CRP (mg/L)

33. ± 55.5

35.1 ± 58.9

30.9 ± 53.6

31.8 ± 52.

0.138

Albumin (g/dL)

4 ± 0.5

4 ± 0.6

4 ± 0.5

4 ± 0.5

0.144

ALT: alanine transaminase, AST: aspartate transaminase; BUN: blood urea nitrogen, CRP: C-reactive protein, GGT: gamma-glutamyl
transpeptidase. In paired comparisons, lower hemoglobin and lower hematocrit levels were correlated with more frequent four times
admissions.
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Table 3. Comparison of number of admissions and interventional methods.
Total

Twice

Thrice

≥ four times

No

4628 (77.5)

2065 (78.1)

1180 (76.5)

1383 (77.4)

Yes

1345 (22.5)

579 (21.9)

363 (23.5)

403 (22.6)

Wedge

1209 (20.2)

520 (19.7)

320 (20.7)

369 (20.7)

Lobectomy

117 (2.0)

51 (1.9)

37 (2.4)

29 (1.6)

Pneumonectomy

19 (0.3)

8 (0.3)

6 (0.4)

5 (0.3)

No

3371 (56.4)

1344 (50.8)

968 (62.7)

1059 (59.3)

Yes

2602 (43.6)

1300 (49.2)

575 (37.3)

727 (40.7)

1

2323 (89.3)

1157 (89.0)

525 (91.3)

641 (88.2)

2

186 (7.1)

88 (6.8)

41 (7.1)

57 (7.8)

3

93 (3.6)

55 (4.2)

9 (1.6)

29 (4.0)

No

3475 (58.2)

1414 (53.5)

978 (63.4)

1083 (60.6)

Yes

2498 (41.8)

1230 (46.5)

565 (36.6)

703 (39.4)

No

1144 (19.2)

519 (19.6)

280 (18.1)

345 (19.3)

Yes

4829 (80.8)

2125 (80.4)

1263 (81.9)

1441 (80.7)

p

Surgical operation
0.477

Operation
0.676

BAE
<0.001

Total number of BAE
0.048

Rigid bronchoscopy
<0.001

Flexible Bronchoscopy
0.490

Total number of flexible bronchoscopy
1

93 (1.9)

43 (2.0)

23 (1.8)

27 (1.9)

2

1298 (26.9)

548 (25.8)

334 (26.4)

416 (28.9)

3

1939 (40.1)

884 (41.6)

506 (40.1)

549 (38.1)

4

1500 (31.1)

651 (30.6)

400 (31.7)

449 (31.2)

Mild

3044 (51.0)

1471 (55.6)

764 (49.5)

809 (45.3)

Moderate

2701 (45.2)

1061 (40.2)

730 (47.3)

910 (51.0)

Massive

228 (3.8)

112 (4.2)

49 (3.2)

67 (3.9)

0.395

Amount of bleeding
<0.001

BAE: bronchial artery embolization. In paired comparisons, four times admissions were significantly less frequent than twice and thrice
in patients undergoing either BAE or rigid bronchoscopy. The amount of bleeding was mostly mild in twice admissions.

In daily practice, hemoptysis is encountered as
simply symptoms of various diseases and a significant
number of the hemoptysis cases may be life-threatening
[1-3]. Management of hemoptysis in daily practice is
challenging due to the following reasons: the fact that
many diseases can cause hemoptysis, only a few centers/
facilities are experienced in managing it, and even fewer
hospitals/centers are qualified enough to intervene massive
hemoptysis competently. This study, conducted in a
specialized and reference center with a robust set of cases
and an immensely experienced team of doctors, can cast
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light on customized management methods according to
the patients’ needs through comparing different modalities.
Abdulmalak et al. analyzed patients with hemoptysis
with a mean age of 62 and female:male ratio as 2:1 [18]. In
parallel, the average age at admission and female to male
ratios are similar in our study. Smoking history was not
found as meaningfully related to hemoptysis in Adelman
et al.’s study where 71% of the patients were found to have
smoking history [19]. Similarly, 45% of our cases were
ever-smoker and no significant relationship was found
between bleeding and smoking history.
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Table 4. Comparison of interventional methods according to the amount of bleeding.
Total

Mild

Moderate

Massive

No

4628 (77.5)

2352 (77.3)

2084 (77.2)

192 (84.2)

Yes

1345 (22.5)

692 (22.7)

617 (22.8)

36 (15.8)

Wedge resection

1209 (20.2)

631 (20.7)

544 (20.1)

34 (14.9)

Lobectomy

117 (2)

51 (1.7)

65 (2.4)

1 (0.4)

Pneumonectomy

19 (0.3)

10 (0.3)

8 (0.3)

1 (0.4)

No

3371 (56.4)

1769 (58.1)

1462 (54.1)

140 (61.4)

Yes

2602 (43.6)

1275 (41.9)

1239 (45.9)

88 (38.6)

1

2323 (89.3)

1159 (90.9)

1082 (87.3)

82 (93.2)

2

186 (7.1)

79 (6.2)

104 (8.4)

3 (3.4)

3

93 (3.6)

37 (2.9)

53 (4.3)

3 (3.4)

No

3475 (58.2)

1798 (59.1)

1545 (57.2)

132 (57.9)

Yes

2498 (41.8)

1246 (40.9)

1156 (42.8)

96 (42.1)

No

1144 (19.2)

581 (19.1)

517 (19.1)

46 (20.2)

Yes

4829 (80.8)

2463 (80.9)

2184 (80.9)

182 (79.8)

p

Operation
0.046

Operation type
0.040

BAE
0.003

Total number of BAE
0.034

Rigid bronchoscopy
0.358

Flexible bronchoscopy
0.922

Total number of flexible bronchoscopy
1

93 (1.9)

48 (1.9)

44 (2)

1 (0.5)

2

1298 (26.9)

669 (27.2)

581 (26.6)

48 (26.4)

3

1939 (40.1)

979 (39.7)

877 (40.2)

83 (45.6)

4

1500 (31.1)

768 (31.2)

682 (31.2)

50 (27.5)

0.640

BAE: bronchial artery embolization. In paired comparisons, in patients undergoing an operational procedure, massive bleeding was
less frequent than mild and moderate, BAE was less frequent in mild hemoptysis than moderate amount. Total number of BAE was
correlated with moderate and mild bleeding amount.
Table 5. Comparison of number of admissions and interventional methods.
Total

Twice

Thrice

≥ four times

BAE
BAE + Rigid
bronchoscopy
BAE

249 (21.4)

134 (23.3)

52 (19.6)

63 (19.5)

915 (78.6)

442 (76.7)

213 (80.4)

260 (80.5)

249 (30.1)

134 (32)

52 (28.3)

63 (28.1)

BAE + operation

578 (69.9)

285 (68)

132 (71.7)

161 (71.9)

Rigid

246 (21.2)

121 (21.5)

51 (19.3)

74 (22.2)

Rigid + BAE

915 (78.8)

442 (78.5)

213 (80.7)

260 (77.8)

Rigid

246 (29.9)

121 (31.1)

51 (27.7)

74 (29.5)

Rigid + operation

578 (70.1)

268 (68.9)

133 (72.3)

177 (70.5)

p
0.305
0.493
0.680
0.702

BAE: bronchial artery embolization.
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Table 6. Comparison of amount of bleeding and interventional methods.
Total

Mild

Moderate

Massive

BAE

249 (21.4)

126 (21.5)

114 (21.3)

9 (20)

BAE + rigid bronchoscopy

915 (78.6)

459 (78.5)

420 (78.7)

36 (80)

BAE

249 (30.1)

126 (30.7)

114 (28.9)

9 (42.9)

BAE + operation

578 (69.9)

285 (69.3)

281 (71.1)

12 (57.1)

Rigid

246 (21.2)

121 (20.9)

116 (21.6)

9 (20)

Rigid + BAE

915 (78.8)

459 (79.1)

420 (78.4)

36 (80)

Rigid

246 (29.9)

121 (29.3)

116 (29.7)

9 (42.9)

Rigid + operation

578 (70.1)

292 (70.7)

274 (70.3)

12 (57.1)

p
0.970
0.373
0.932
0.415

BAE: bronchial artery embolization.

Table 7. Comparison of follow-up duration (days) according to interventional methods.
N

Mean ± SD

BAE

249

1416.9 ± 650.6

BAE + Rigid bronchoscopy

915

1295.7 ± 664.8

BAE

249

1416.9 ± 650.6

BAE + operation

578

1234 ± 672.2

Rigid bronchoscopy

246

1382.8 ± 659.5

Rigid bronchoscopy + BAE

915

1295.7 ± 664.8

Rigid bronchoscopy

246

1382.8 ± 659.5

Rigid bronchoscopy + operation

578

1266.4 ± 670

P
0.011
<0.001
0.068
0.022

BAE: bronchial artery embolization.

In European countries, an underlying cause is reported
to be identifiable in 50% of hemoptysis patients, and this
cause is mostly lung-related [18]. In other studies, the
underlying cause of hemoptysis could not be revealed in
5%–34% of patients admitted with hemoptysis [20].
Lung diseases are categorized generally as (although
subcategories may differ slightly) the following: airborne infections, bronchial carcinomas/metastases,
bronchiectasis/cystic fibrosis, pulmonary edema/mitral
stenosis, and TB [18]. Massive hemoptysis is most
frequently caused by TB, bronchiectasis, mycetoma,
and lung cancer, respectively; TB is especially the most
prevalent reason in endemic regions [3]. In present study,
the most encountered causes in recurrence and frequent
admissions were lung cancer followed by bronchiectasis,
TB sequela, and active TB. This departure from literature
may be explained by our hospital’s being a reference
hospital and thus the referral of a significant proportion
of malignant cases to our center. As stated above, the
immersive hemoptysis experience of our hospital is also
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a reason for our routine admission of these patients from
various other hospitals. Furthermore, because our study
purposefully covers only the patients who had to be
hospitalized for treatment and who had been admitted to
the hospital at least twice, we automatically excluded the
patients whose hemoptysis is rather minimal. While the
majority of hemoptysis cases comprise light bleeding, 5%–
15% are reported as massive bleeding [3-4]. In line with
the literature, 3.8% of our patients were bleeding massively.
Flexible bronchoscopy, used for verification of
bleeding, bleeding localization, endobronchial blocker
placement, selective intubation, and clot extraction, is the
most frequently used interventional method for diagnostic
and therapeutic purposes in hemoptysis [3,20,21]. It can
detect the focus of bleeding with 73%–93% certainty
[13-22]. It is not only important for better examination
of subsegments and detection of bleeding focus but also
it can control bleeding in acute cases as bronchoscopy
provides bufferization. Other tools for bleeding control are
medical processes aiming the bleeding focus through as
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epinephrine, tranexamic acid, and cold saline [13-23]. In
our study, in parallel to the literature, 80% of the patients
underwent flexible bronchoscopy. It was specifically opted
for in mild (51%) and moderate (45%) cases.
Rigid bronchoscopy may be preferred over flexible
bronchoscopy in the presence of following conditions:
the ability to simultaneously provide airway safety and
intervention, allowing isolation of the primary bronchus,
providing a larger channel for intervention and thus
enabling rapid removal of sizeable clots, allowing additional
intervention of thermal ablation or cauterization and also
allowing the use of additional tools such as bronchial
balloon or tamponades [23-24]. In line with the literature,
in our study, it is observed that rigid bronchoscopy was
prevalent in mild and moderate cases while in massive
bleeding cases, compared to other treatment modalities,
it was the first and most preferred interventional method.
In the analysis by Panda et al. where 22 studies were
assessed, the success rate of BAE was detected as 70%–90%
and the recurrence rate of hemoptysis in BAE-applied
patients who also had aspergillum, TB, and bronchiectasis
rose to a value as high as 58% [9,25]. In our study, %43.6
underwent BAE procedure and those patients with a high
amount of bleeding and thus with frequent admissions to
hospital were especially referred to undergo BAE. It was
the most preferred interventional method to be followed
by rigid bronchoscopy in our study.
Surgical resections are increasingly less preferred in
recent years due to the following reasons: the rather exclusive
application of pulmonary resection under emergency
conditions in patients not otherwise responding to medical
treatment, pneumonectomy being favored as the radical
surgical method, and postoperation complications [26].
Similarly, in our study, surgical resections was performed
solely in critical cases of massive life-threatening bleeding
when the source of bleeding could be detected and the cause
of bleeding could be quenched via interventional methods
[27]. In the multicenter study by Lee et al., less than 1% of
hemoptysis patients who were defined as emergency cases
underwent surgical operation [28]. We observed in our study
that 22.5% of the patients underwent surgical resection, of
which 90% were wedge resection. As given above, because
our center accepts mostly emergency cases and it is a primary
referral center for cases such as lung cancer, bronchiectasis,
and mycetoma which have specific causes requiring surgical
operation, the higher rate of resections compared to that in

the literature is not surprising. It should also be clarified that
of these surgical methods, parenchymal protective surgery
was the main one.
The main limitation of our study is that the retrospective
design could not eliminate the impact of compounding
factors such as medical history and previous medical
treatment on the intervention success or failure. Also, our
hospital’s being a reference center may have an inevitable
impact on the case profile, thus the results. Because our
patients were rather severe cases and referred from other
various centers, the influence of their very initial hemoptysis
on the intervention success could not be calculated.
Finally, a detailed analysis of different diseases could not
be given in this study. We believe that a prospective design
where bleeding amount is set beforehand would guide
for better practice and testing the retrospective findings.
On the other hand, the high number of patients who
have been followed up in a specific reference experienced
center, giving an overall result of interventional methods
is the strength of this study. In conclusion, hemoptysis
patients comprise a medical emergency requiring frequent
emergency room visits and hospitalization. This inevitably
makes this patient group very important for management
prospects and cost-effectiveness purposes. The extant
literature involves studies with rather small number of
cases where treatment modalities’ comparison is not
sufficiently satisfactory. Our study is contributory in this
respect with its set of severe patients, indicating that the
combined use of BAE and rigid bronchoscopy could be
considered for successful hemoptysis control.
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